Latest Meta-Analysis: Nattokinase’s Effect on Thrombus Resolution Time

Nattokinase & Thrombus Resolution

Cardiovascular diseases remain the leading cause of premature death globally, with thrombus formation playing a critical role. Nattokinase, an enzyme derived from fermented soybeans (natto), has drawn attention for its fibrinolytic properties, potentially aiding in cardiovascular protection. A 2023 systematic review and meta-analysis of randomized controlled trials (RCTs) evaluated the effects of nattokinase supplementation specifically on cardiovascular risk factors, including thrombus resolution. A total number of 8 independent RCTs are included in this study.

Evaluating Nattokinase's Cardiovascular Impact

Researchers aimed to assess whether nattokinase supplementation effectively influences key cardiovascular risk factors such as blood lipids, blood pressure, and coagulation parameters, providing clear evidence-based guidance for its clinical use.

Key Results: What the Meta-Analysis Revealed

End point	Nattokinase Supplementation Results
Total Cholesterol	Slightly increased levels (p<0.0001)
HDL Cholesterol	Mixed results; reduction with low-dose but significantly increased with high-dose (p=0.01)
LDL Cholesterol	Slight increase at low doses and neutral at high doses; no significance observed.
Triglycerides	No significant impact (p=0.71)
Blood Pressure	Significant reduction in both SBP (–3.45 mmHg) and DBP (–2.32 mmHg); p<0.00001
Blood Glucose	Slight increase (+0.40 mg/dL; p<0.0001)
Adverse Events	No significant adverse events reported

*SBP: Systolic Blood Pressure; DBP: Diastolic Blood Pressure

Notably, nattokinase demonstrated consistent efficacy in reducing systolic and diastolic blood pressure, confirming its potential as an adjunctive therapy for hypertension. However, the lipid-lowering effect appears dependent on dosage and treatment duration, with high-dose, long-term administration potentially necessary to observe beneficial impacts on cholesterol levels.

FAQ

Q: Is nattokinase a proven alternative to traditional anticoagulants?
A: Not entirely; nattokinase supports fibrinolysis but should not replace prescribed anticoagulants without medical supervision.

Q: What is the ideal nattokinase dosage for cardiovascular benefits?
A: Clinical studies generally utilize dosages ranging from 2,000 to 8,000 FU daily, with higher doses possibly necessary for cholesterol and thrombus reduction.

Q: Can nattokinase supplementation cause significant side effects?
A: Current evidence shows nattokinase as safe with no notable adverse effects, even at higher dosages used clinically.

Takeaways

Blood Pressure Control

Nattokinase effectively lowers blood pressure, beneficial as complementary support for hypertension management.

Dosage Matters

Positive impacts on cholesterol and thrombus resolution likely require higher dosages (>2000 FU/day) and extended supplementation periods.

Safe Profile

High compliance and absence of significant adverse events underscore nattokinase’s safety, even at higher dosages.

Combination Therapy

Enhanced effects potentially achieved when combined with a heart-healthy lifestyle and standard cardiovascular medications.

References

Xinmin Li et al., “Nattokinase Supplementation and Cardiovascular Risk Factors: A Systematic Review and Meta-Analysis of Randomized Controlled Trials”, 2023 (doi: https://doi.org/10.31083/j.rcm2408234)